Does UPMC Health Plan Cover Forteo (Teriparatide)?

What Is Forteo and Why Does Coverage Matter?

Forteo is an anabolic bone agent, not just an antiresorptive drug. That distinction drives every coverage decision UPMC Health Plan makes about it.

Teriparatide is a recombinant fragment of human parathyroid hormone (PTH 1-34). Given once daily as a 20 mcg subcutaneous injection, it stimulates osteoblast activity and builds new bone rather than simply slowing its breakdown. The key Fracture Prevention Trial (Neer et al., NEJM 2001) enrolled 1,637 postmenopausal women and showed a 65% reduction in new vertebral fractures (relative risk 0.35, 95% CI 0.22 to 0.55, P<0.001) compared to placebo over a median of 21 months. Non-vertebral fragility fractures fell by 53%.

Those results are why teriparatide is reserved for severe or high-risk osteoporosis, specifically patients with a T-score at or below -2.5 combined with a prior fragility fracture, or a T-score below -3.5 regardless of fracture history. The American Association of Clinical Endocrinologists (AACE) 2020 Clinical Practice Guidelines (Camacho et al., Endocr Pract 2020) list teriparatide as a first-line option only in patients at "very high" fracture risk, which UPMC Health Plan uses as part of its medical necessity criteria.

Why Coverage Is Complicated

Because Forteo costs roughly $3,200 to $3,900 per month at average wholesale price, payers classify it as a specialty drug. UPMC Health Plan follows the standard managed-care approach of placing specialty agents on the highest formulary tiers and requiring step therapy through lower-cost alternatives first. The FDA-mandated 24-month lifetime cap (FDA label for Forteo) also figures into utilization management: plans know the exposure period is finite, which paradoxically makes authorization battles more common because the financial stakes per episode are high.

Who Qualifies Clinically

The FDA approved teriparatide for three populations: postmenopausal women with osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis at high fracture risk, and men and women with glucocorticoid-induced osteoporosis at high fracture risk (FDA NDA 021318). UPMC Health Plan's prior authorization forms track these three indications directly.

UPMC Health Plan Formulary Placement and Prior Authorization Requirements

UPMC Health Plan covers Forteo on its specialty drug tier across commercial HMO, PPO, and Medicare Advantage plans, but the specific tier number and cost-share vary by product.

Formulary Tier Structure

On most commercial UPMC Health Plan products, specialty drugs occupy Tier 4 or Tier 5. Tier 4 specialty drugs carry a coinsurance of 20 to 33% after deductible, which on a $3,500/month drug translates to $700 to $1,155 per fill before out-of-pocket maximums apply. On UPMC for Life Medicare Advantage plans, Forteo typically sits at the catastrophic coverage tier until the beneficiary exits the coverage gap, after which standard cost-sharing resumes. Members should pull their specific Summary of Benefits and Coverage (SBC) document, available through the UPMC Health Plan member portal, to confirm the exact tier.

Prior Authorization Criteria

UPMC Health Plan's prior authorization criteria for Forteo generally require all of the following:

• A diagnosis of osteoporosis confirmed by DXA scan showing T-score of -2.5 or below, or a prior low-trauma (fragility) fracture.
• Documentation that the member meets one of the three FDA-approved indications.
• A trial and documented intolerance or inadequate response to at least one oral bisphosphonate (typically alendronate 70 mg weekly or risedronate 35 mg weekly) for at least three to six months, unless a specific contraindication is documented.
• A physician attestation that anabolic therapy is appropriate given fracture risk severity.

The AACE and American College of Rheumatology (ACR) both support bypassing bisphosphonate step therapy in very high-risk patients, specifically those with a prior hip or vertebral fracture plus T-score below -2.5, or patients on chronic systemic glucocorticoids at doses of 7.5 mg/day or more of prednisone equivalent for 90 days or longer (Buckley et al., Arthritis Rheumatol 2017). If your prescribing physician documents one of these high-risk scenarios, UPMC Health Plan's medical director may waive step therapy under the plan's step-therapy exception process.

Glucocorticoid-Induced Osteoporosis: A Special Case

Patients on long-term glucocorticoids deserve particular attention. A meta-analysis of 27 trials (N=3,286) published in the Cochrane Database (Homik et al., Cochrane 1999, updated reviews through 2022) confirmed that bisphosphonates reduce fracture risk in glucocorticoid-treated patients, which is why payers still list them first. The ACR 2017 guideline (Buckley et al.), however, recommends teriparatide as preferred over bisphosphonates when baseline fracture risk is very high, defined as prior fracture or T-score below -2.5 in a patient already on glucocorticoids. This guideline language is your physician's strongest use point in a prior authorization request.

How to Get Prior Authorization Approved

Getting a Forteo prior authorization approved on the first submission depends almost entirely on the completeness of the documentation package sent to UPMC Health Plan's pharmacy benefit manager.

Required Documentation Checklist

Your prescribing physician should submit all of the following in a single fax or electronic submission:

1. Completed UPMC Health Plan specialty prior authorization form (available at upmchealthplan.com or through the physician's office portal).
2. DXA scan report showing current T-score and Z-score at lumbar spine and total hip.
3. Radiology or emergency records documenting any prior fragility fracture.
4. A list of all prior osteoporosis treatments tried, with dates and reason for discontinuation or inadequate response.
5. If requesting step-therapy exception: documentation of contraindication, intolerance (e.g., esophageal disease precluding oral bisphosphonates, renal impairment with GFR <35 mL/min/1.73 m² for oral bisphosphonates), or very high fracture risk per AACE or ACR criteria.
6. The physician's clinical notes supporting the prescription.

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) estimates that osteoporosis causes approximately two million fractures per year in the United States, with an associated annual cost of roughly $19 billion (BHOF Clinician's Guide). Framing the prior authorization request in terms of fracture prevention cost-offsets can sometimes move a medical director review in the member's favor, though the primary requirement remains clinical documentation.

Timelines to Expect

Under Pennsylvania insurance regulations, UPMC Health Plan must respond to standard prior authorization requests within three business days and urgent requests within 24 hours. If the initial request is pended for more information, the clock restarts. Plan for a seven to fourteen day turnaround in most cases. Do not delay the DXA scan or fracture documentation gathering, because incomplete submissions are the single most common reason for initial denials.

What Happens If UPMC Health Plan Denies Forteo Coverage

A denial is not the end of the road. The appeals process has multiple levels, and specialty drug denials are overturned at meaningful rates.

First-Level Internal Appeal

File the appeal within 60 days of receiving the denial letter. The appeal must include the original prior authorization package plus a detailed physician letter addressing the specific denial reason cited by UPMC Health Plan. If the denial cites step therapy non-completion, the letter should invoke Pennsylvania's Step Therapy Exception Act (Act 44 of 2017), which requires commercial health insurers to grant step therapy exceptions when a prior-authorization drug is contraindicated, when the patient has already tried the required drugs, or when the required drugs are expected to be ineffective based on patient-specific medical or genetic information.

Published CMS data on Medicare Advantage appeals (CMS Medicare Advantage Appeals Data 2023) indicate that approximately 40 to 50% of specialty drug denials are reversed at the first internal appeal level when supported by physician documentation.

External Independent Review

If the internal appeal fails, Pennsylvania law gives members the right to an external independent review by an Independent Review Organization (IRO) contracted with the Pennsylvania Insurance Department. The IRO's decision is binding on the insurer for coverage determinations. Request this within four months of the final internal denial.

Expedited Appeals for Urgent Situations

If a treating physician certifies that waiting for standard appeal timelines poses a serious threat to the patient's health, UPMC Health Plan must render an expedited appeal decision within 72 hours. Patients with acute vertebral fractures or those on high-dose glucocorticoids with rapidly declining bone density may qualify for this pathway.

Forteo Cost and Patient Assistance Programs

Even with coverage, specialty tier cost-sharing makes Forteo expensive. Several programs can close that gap.

Eli Lilly Patient Assistance Program

Eli Lilly offers the Lilly Cares Foundation Patient Assistance Program, which may provide Forteo at no cost to patients who meet income criteria (generally at or below 200 to 250% of the Federal Poverty Level) and who are uninsured or underinsured. Applications are submitted through lillycares.com. Processing takes approximately two to four weeks.

Lilly Savings Card (Commercial Insurance Only)

For commercially insured patients, Lilly's Forteo Savings Card may reduce out-of-pocket costs to as low as $25 to $50 per month, subject to eligibility restrictions and annual caps. This program is not available to Medicare or Medicaid beneficiaries due to federal anti-kickback rules.

Medicare Extra Help / Low-Income Subsidy

Medicare Part D beneficiaries who qualify for Extra Help (Low-Income Subsidy, LIS) pay no more than a nominal copay (approximately $11.20 in 2024 for full LIS beneficiaries) for covered specialty drugs. Applications are available through the Social Security Administration (ssa.gov). A study published in Health Affairs found that LIS enrollment reduces specialty drug abandonment rates by 38% (Doshi et al., Health Affairs 2016).

State Pharmaceutical Assistance Programs

Pennsylvania's PACE (Pharmaceutical Assistance Contract for the Elderly) and PACENET programs provide additional drug cost assistance to Pennsylvania residents aged 65 or older who meet income thresholds. These stack on top of Medicare Part D, potentially eliminating remaining cost-sharing for eligible UPMC for Life members.

Clinical Alternatives If Forteo Coverage Is Denied

If UPMC Health Plan ultimately declines to cover Forteo after exhausting appeals, your physician has several clinically appropriate alternatives to consider.

Tymlos (Abaloparatide)

Abaloparatide (Tymlos, Radius Health) is a PTH-related protein analog approved in 2017 for postmenopausal women with osteoporosis at high fracture risk. The ACTIVE trial (N=2,463) showed a 43% reduction in new vertebral fractures vs. Placebo over 18 months (Miller et al., JAMA 2016). Tymlos may be covered on a different formulary tier than Forteo at UPMC Health Plan, and a specialty prior authorization is also required, but the step-therapy history from a prior Forteo request carries over and can simplify the Tymlos authorization.

Prolia (Denosumab)

Denosumab 60 mg subcutaneous every six months (Prolia, Amgen) is an anti-RANK-L monoclonal antibody with strong fracture reduction data. The FREEDOM trial (N=7,808) showed a 68% reduction in new vertebral fractures over 36 months (Cummings et al., NEJM 2009). UPMC Health Plan typically places Prolia on a lower specialty tier than teriparatide, and prior authorization is usually easier to obtain for patients who have already tried a bisphosphonate.

Evenity (Romosozumab)

Romosozumab (Evenity, Amgen/UCB) is a sclerostin inhibitor approved in 2019 for postmenopausal women with osteoporosis at high fracture risk. The ARCH trial (N=4,093) showed a 48% reduction in new vertebral fractures compared to alendronate at 12 months (Saag et al., NEJM 2017). Romosozumab carries an FDA boxed warning for increased risk of myocardial infarction and stroke; it is contraindicated in patients with a history of MI or stroke within the preceding year. UPMC Health Plan covers it with similar prior authorization requirements to Forteo.

Bisphosphonate Optimization

If anabolic therapy is deferred, bisphosphonates remain effective first-line agents. Alendronate 70 mg weekly reduces vertebral fracture risk by approximately 47% and hip fracture risk by 51% in women with prior vertebral fracture (Black et al., NEJM 1996). Intravenous zoledronic acid 5 mg annually (Reclast) bypasses GI tolerability issues and is covered at a lower tier by most UPMC Health Plan products.

Sequencing: What Comes After Forteo

The FDA-mandated 24-month lifetime maximum for teriparatide means planning for post-Forteo therapy is as clinically important as obtaining the initial authorization.

Why Sequential Antiresorptive Therapy Matters

Bone mineral density gains from teriparatide are partially lost if antiresorptive therapy is not started promptly after the course ends. The DATA-Switch trial (Leder et al., NEJM 2015) demonstrated that patients who transitioned from teriparatide to denosumab achieved greater BMD increases than those transitioning to alendronate. UPMC Health Plan will cover the sequential antiresorptive agent under standard criteria; your prescribing physician should proactively plan and authorize this before month 20 of teriparatide therapy to avoid a coverage gap.

Monitoring During Forteo Therapy

Standard monitoring during teriparatide treatment includes:

• Serum calcium at baseline and one month after initiation (teriparatide transiently raises serum calcium; hypercalcemia occurs in approximately 11% of patients per the FDA label).
• DXA scan at 12 months to document treatment response.
• Serum creatinine to confirm ongoing renal tolerability (teriparatide is not recommended in patients with severe renal impairment).

The Endocrine Society Clinical Practice Guideline on Osteoporosis in Men (Watts et al., J Clin Endocrinol Metab 2012) recommends DXA monitoring every one to two years in men receiving teriparatide and transition to antiresorptive therapy at 24 months. UPMC Health Plan may require this monitoring data for renewal authorization at the 12-month mark.

UPMC Health Plan Product Variations: Commercial vs. Medicare Advantage

Not all UPMC Health Plan products handle Forteo identically. The plan type you or your patient is enrolled in changes the formulary tier, cost-sharing, and appeals pathway.

Commercial (Employer-Sponsored and Individual Market) Plans

Commercial UPMC Health Plan members are subject to Pennsylvania's Step Therapy Exception Act. This is a meaningful protection. Physicians can invoke it directly in the prior authorization request letter if the patient has a contraindication to bisphosphonates or meets the very-high-risk fracture criteria in the AACE 2020 guidelines. The Pennsylvania Insurance Department enforces compliance; filing a complaint with the department accelerates insurer responsiveness.

UPMC for Life Medicare Advantage Plans

Medicare Advantage members at UPMC for Life are governed by CMS Medicare Part D rules rather than Pennsylvania state step-therapy laws. CMS requires Medicare Advantage plans to have an exceptions and appeals process, but the specific timeline and documentation standards differ from commercial plans. The CMS Medicare Prescription Drug Manual (CMS Pub 100-18) outlines the exception request process in Chapter 18. Medicare Advantage members should request a Coverage Determination, then an Redetermination, then an Independent Review Entity (IRE) review if denied at first level.

UPMC Community HealthChoices (Medicaid Managed Care)

Pennsylvania Medicaid recipients enrolled in UPMC Community HealthChoices have Forteo coverage governed by the Pennsylvania Medicaid Preferred Drug List (PDL). Teriparatide is a non-preferred drug on the Pennsylvania PDL and requires a prior authorization with clinical criteria similar to but distinct from commercial criteria. The Pennsylvania DHS Bureau of Pharmacy Services publishes the current PDL at dhs.pa.gov. Medicaid prior authorization denials follow a separate grievance pathway through the Office of Medical Assistance Programs.

Practical Steps for Patients and Prescribers

Getting Forteo covered at UPMC Health Plan follows a predictable sequence once you know what the plan requires.

Step 1: Confirm Formulary Status Before Prescribing

Call the member services number on the back of the insurance card and ask the following specific questions: Is teriparatide (Forteo) on the formulary? What tier? Is prior authorization required? What is the step therapy requirement? Get a reference number for the call. This 10-minute call prevents surprise denials at the pharmacy.

Step 2: Submit a Complete Prior Authorization Package on Day One

Incomplete submissions are returned and restart the clock. Use the documentation checklist above. Attach a cover letter from the prescribing physician that explicitly references the AACE 2020 fracture risk categories and the member's specific T-score, fracture history, and prior therapy.

Step 3: Use the Specialty Pharmacy Network

UPMC Health Plan contracts with specific specialty pharmacies for self-injectable biologics. Forteo dispensed through an out-of-network specialty pharmacy may be covered at a significantly higher cost-share or denied outright. Verify the dispensing pharmacy is in-network before the prescription is sent.

Step 4: Apply for Manufacturer Assistance in Parallel

Submit the Lilly Cares or Lilly Savings Card application on the same day the prior authorization is filed. Processing takes two to four weeks; having the assistance program in place before the first fill avoids a payment gap even if authorization is delayed.

Step 5: Calendar the 12-Month Renewal

UPMC Health Plan's prior authorization for Forteo is typically approved for six to twelve months and requires renewal. Missing the renewal window interrupts therapy. Set a calendar reminder 60 days before the authorization expiration date and resubmit with updated DXA and clinical notes.